^
Association details:
| Biomarker: | TROP2 expression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Trodelvy (sacituzumab govitecan-hziy) (Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
Excerpt:
Mice bearing Trop-2+ human gastric carcinoma xenografts (NCI-N87) were given 2 treatments 7 days apart...Animals treated with the ADCs having a DAR of 6.89 had a significantly improved median survival time...These results demonstrate that even in tumors that continued to grow after exposure to SN-38 via a non-specific ADC, a significantly enhanced therapeutic response could be achieved when treated with the Trop-2-specific IMMU-132.
DOI:
10.18632/oncotarget.4318
